BioMarin Pharmaceutical, Inc. (BMRN)
57.82
+1.27
(+2.25%)
USD |
NASDAQ |
Jun 09, 15:13
BioMarin Pharmaceutical Research and Development Expense (Quarterly) : 178.80M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 210.17M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Incyte Corp. | 515.90M |
| Mirum Pharmaceuticals, Inc. | 97.84M |
| Cytokinetics, Inc. | 92.15M |